| Schedule of estimated using the Black-Scholes pricing model |
|
|
|
|
|
|
|
|
| |
|
As of Grant Date |
| |
|
November 2025 registered direct offering |
| |
|
Investors warrants |
|
Placement agents warrants |
| Number of shares exercisable* |
|
|
172,069 |
|
|
|
8,603 |
|
| Exercise price* |
|
$ |
7.5 |
|
|
$ |
25 |
|
| Stock price* |
|
$ |
9.8 |
|
|
$ |
9.8 |
|
| Expected years |
|
|
5 |
|
|
|
3 |
|
| Risk-free interest rate |
|
|
3.69 |
% |
|
|
3.58 |
% |
| Expected volatility |
|
|
98.15 |
% |
|
|
98.15 |
% |
| Fair value |
|
$ |
1,323,369 |
|
|
$ |
36,568 |
|
* Giving retroactive effect to the 1-for-10 reverse
stock split effected on June 4, 2026.
|